Earnings News

Latest earnings news and updates for US-listed public companies.

📣 Get earnings alerts and analysis

SalMar - Strong biological development throughout the quarter

“In short, we are pleased with the biological development during the quarter. This lays the foundation for increased volume and positive cost development in the second half of the year. Financially...

How does SalMar's biological growth and cost trajectory compare with its main competitors in the aquaculture sector for the upcoming year? What are the implications of the weak Q2 financial performance and poor price achievement on SalMar's margins and cash flow outlook? How will the reported strong biological development translate into increased production volume and affect SalMar's supply dynamics in H2 2025?
Symbol: SALM
17 days ago
Read more globenewswire

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year end...

How will the half‑year results impact Telix's valuation multiples relative to peers in the pharma sector and affect short‑term trading activity? What are the details of the announced investments for long‑term growth—capital allocation, R&D pipeline milestones, and potential dilution or financing needs? How does the reported revenue and earnings growth compare to Telix's guidance and analyst expectations for H1 2025?
Symbol: TLX
18 days ago
Read more globenewswire

Microsoft's gutting of discounts for some clients likely baked into guidance, analyst says

In getting rid of enterprise discounts for certain products, some Microsoft clients could face significant price increases.

How might this pricing strategy shift influence Microsoft’s competitive positioning relative to other cloud providers? What is the expected client churn risk and its impact on Microsoft’s enterprise business? How will the removal of discounts affect Microsoft's projected revenue and earnings guidance?
Symbol: MSFT
18 days ago
Read more cnbc_tech

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

ROCKVILLE, Md. and SUZHOU, China, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma,” th...

How might the recent updates affect the share structure (e.g., dilution from financing) and the stock’s short‑term trading dynamics relative to peers in the oncology biotech space? Which clinical trial milestones or regulatory events are expected in the near term, and what could be their impact on the company's valuation? What are the key financial metrics (revenue, net loss, cash position) from the six‑month results and how do they compare to the company's guidance and prior periods?
Symbol: AAPG
18 days ago
Read more globenewswire

NUTEX HEALTH PROVIDES FINANCIAL REPORTING UPDATE

HOUSTON, Aug. 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art mi...

What are the implications of the reported performance on Nutex Health's competitive positioning and growth prospects in the integrated healthcare sector? How will the update affect Nutex Health's valuation multiples and potential price target adjustments? What are the key financial metrics and guidance updates disclosed in the report, and how do they compare to consensus estimates?
Symbol: NUTX
18 days ago
Read more prnewswire

Sabio to Announce Second Quarter 2025 Results on August 26th, 2025

- Conference call to be hosted on Wednesday, August 27th at 10:00 a.m. ET - TORONTO and LOS ANGELES, Aug. 20, 2025 /PRNewswire/ -- Sabio Holdings (TSXV: SBIO) (OTCQB: SABOF) (the "Company" or "Sabi...

Are there any strategic updates—such as new partnerships, product launches, or capital allocation plans—outlined in the earnings call that could impact the company's long‑term valuation? What key metrics (e.g., revenue growth, client acquisition, ad spend efficiency) are highlighted in the results and how do they stack up against peers in the ad-tech sector? How will Sabio's Q2 2025 earnings and guidance compare to market expectations and affect the stock's short-term price movement?
Symbol: SBIO
18 days ago
Read more prnewswire